Uptake of 2-[f]fluoro-2-deoxy-d-glucose in uterine leiomyoma: imaging of four patients by coincidence positron emission tomography

Nuclear Medicine Communications

Volumn 25, Issue 9, 2004, Pages 941-945

  Ak, İlknur ^a   Özalp, Sinan ^a   Yalcin T ^a   Zor, Evren ^a   Vardareli, Erkan ^a  

^a Osmangazi University Faculty of Medicine   (United States)

Author keywords

Coincidence PET; Uterine leiomyoma

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; BASIC FIBROBLAST GROWTH FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CASE REPORT; COMPARATIVE STUDY; FEMALE; HUMAN; LEIOMYOMA; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; UTERUS CANCER; VALIDATION STUDY; CANCER SCINTISCANNING; CELL PROLIFERATION; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DRUG UPTAKE; FEMALE GENITAL TRACT TUMOR; HISTOPATHOLOGY; RADIODIAGNOSIS; SMOOTH MUSCLE FIBER; UTERUS MYOMA;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LEIOMYOMA; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; UTERINE NEOPLASMS;

EID: 4444241082     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200409000-00012     Document Type: Article

References (38)

1. Buttram VJ, Reiter R. Uterine leiomyomata: Etiology, symptomatology, and management. Fertil Steril 1981; 36:433-445.
2. Cramer S, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990; 94:435-438.
3. Mayer D, Shipilov V. Ultrasonography and magnetic resonance imaging of uterine fibroids. Obstet Gynecol Clin North Am 1995; 22:667-725.
4. Hricak H, Tscholakoff D, Heinrichs L, Fisher M, Dooms G, Reinhold C, Jaffe R. Uterine leiomyomas, correlation of MR, histopathologic findings, and symptoms. Radiology 1986; 158:385-391.
5. Dudiak C, Turner D, Patel S, Archie J, Silver B, Norusis M. Uterine leiomyomas in the infertile patient: preoperative localization with MR imaging versus US and hysterosalpingography. Radiology 1988; 167:627-630.
6. Zawin M, McCarthy S, Scoutt L, Comite F. High-field MRI and US evaluation of the pelvis in women with leiomyomas. Magn Reson Imaging 1990; 8:371-376.
7. Ak I, Stokkel M, Pauwels E. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. [Review] J Cancer Res Clin Oncol 2000; 126:560-574.
8. Yuan C, Liu R, Wang P, Ng H, Yeh S. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report. J Reprod Med 1999; 44:775-778.
9. 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res 2001; 21:3691-3694.
10. 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker. Neoplasma 2002; 49:329-333.
11. Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging 2002; 29:797-803.
12. Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Fujibayashi Y, Yonekura Y, et al. Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range. Ann Nucl Med 2002; 16:491-493.
13. 18F-fluorodeoxyglucose in advanced cervical cancer with negative magnetic resonance imaging findings. Oncol Rep 2002; 9:1289-1292.
14. Belhocine T, Thille A, Fridman V, Albert A, Seidel L, Nickers P, et al. Contribution of whole-body 18FDG PET imaging in the management of cervical cancer. Gynecol Oncol 2002; 87:90-97.
15. 18F-FDG PET in patients with cervical cancer. J Nucl Med 2003; 44:347-352.
16. Lin W, Hung Y, Yeh L, Kao C, Yen R, Shen Y. Usefulness of (18)F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings. Gynecol Oncol 2003; 89:73-76.
17. Singh A, Grigsby P, Dehdashti F, Herzog T, Siegel B. FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma. Int J Radiat Oncol Biol Phys 2003; 56:489-493.
18. Havrilesky L, Wong T, Secord A, Berchuck A, Clarke-Pearson D, Jones E. The role of PET scanning in the detection of recurrent cervical cancer. Gynecol Oncol 2003; 90:186-190.
19. Umesaki N, Tanaka T, Miyama M, Kawamura N, Ogita S, Kawabe J. Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging. Gynecol Oncol 2001; 80:372-377.
20. Umesaki N, Tanaka T, Miyama M, Ogita S, Kawabe J, Okamura T. Positron emission tomography using 2-[(18)F] fluoro-2-deoxy-D-glucose in the diagnosis of uterine leiomyosarcoma: a case report. Clin Imaging 2001; 25:203-205.
21. Cher S, Lay E. Positron emission tomographic-computed tomographic imaging of a uterine sarcoma. Clin Nucl Med 2003; 28:443-444.
22. Yamashita Y, Torashima M, Takahashi M, Tanaka N, Katabuchi H, Miyazaki K. Hyperintense uterine leiomyoma at T2-weighted MR imaging: differentiation with dynamic enhanced MR imaging and clinical implications. Radiology 1993; 189:721-725.
23. Kier R. Magnetic resonance imaging of the uterus. MRI Clin North Am 1994; 2:189-210.
24. Lehrman B, Nisenbaum H, Glasser S, Najar D, Rosen M. Uterine myolipoma: magnetic resonance imaging, computed tomographic, and ultrasound appearance. J Ultrasound Med 1990; 9:665-668.
25. Ueda H, Togashi K, Konishi I, Kataoka ML, Koyama T, Fujiwara T, et al. Unusual appearances of uterine leiomyomas: MR imaging findings and their histopathologic backgrounds. Radiographics 1999; 19:131-145.
26. Murase E, Siegelman E, Outwater E, Perez-Jaffe L, Tureck R. Uterine leiomyomas: histopathologic features, MR imaging findings, differential diagnosis, and treatment. Radiographics 1999; 19:1179-1197.
27. Kim S, Sim J, Seong C. Interface vessels on color/power Doppler US and MRI: A clue to differentiate subserosal uterine myomas from extrauterine tumors. J Comput Assist Tomogr 2001; 25:36-42.
28. Flier J, Mueckler M, Usher P, Lodish H. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987; 235:1492-1495.
29. Oheir P. Metabolism and transport of glucose and FDG. In: Ruhlman J, Oheir P, Biersack H (editors): PET in Oncology: Basic and Clinical Applications. Berlin, Heidelberg, New York:Springer; 1999, pp 43-57.
30. Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990; 170:223-230.
31. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33:1972-1980.
32. Brown R, Leung J, Fisher S, Frey K, Ethier S, Wahl R. Intratumoural distribution of tritiated luorodeoxyglucose in breast carcinoma: are inflammatory cells important?. J Nucl Med 1995; 36:1854-1861.
33. Mangrulkar R, Ono M, Ishikawa M, Takashima S, Klagsbrun M, Nowak R. Isolation and characterization of heparin-binding growth factors in human leiomyomas and normal myometrium. Biol Reprod 1995; 53:363-346.
34. Stewart E, Nowak R. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update 1996; 2:295-306.
35. Dou Q, Zhao Y, Tarnuzzer R, Rong H, Williams R, Schultz G, et al. Suppression of transforming growth factor-beta (TGF beta) and TGF beta receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy. J Clin Endocrinol Metab 1996; 81:3222-3330.
36. Chegini N, Tang X, Ma C. Regulation of transforming growth factor-beta1 expression by granulocyte macrophage-colony-stimulating factor in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab 1999; 84:4138-4143.
37. Muck B, Hommel G. The glycogen content of blood and uterine tissue in women with myoma and endometriosis [Author's translation]. Arch Gynakol 1976; 221:129-137.
38. Kao C. FDG uptake in a huge uterine myoma. Clin Nucl Med 2003; 28:249.